このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Rubius Therapeutics 過去の業績

過去基準チェック /06

Rubius Therapeutics は平均年間 8.6% の収益成長を遂げていますが、Biotechs 業界では年間収益成長率となっています。15.5% です。

主要情報

8.6%

収益成長率

11.0%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-1,187.4%
ネット・マージン	n/a
前回の決算情報	31 Dec 2022

Recent updates

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Oct 28

Our Read On Rubius Therapeutics

Jul 11

Rubius Therapeutics EPS beats by $0.02

May 10

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Feb 25

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Rubius Therapeutics EPS misses by $0.01

Nov 09

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

Oct 28

収支内訳

Rubius Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:RUBY 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Dec 22	-180	31	96
30 Sep 22	-215	44	135
30 Jun 22	-201	48	149
31 Mar 22	-207	52	152
31 Dec 21	-197	53	142
30 Sep 21	-182	53	127
30 Jun 21	-174	53	118
31 Mar 21	-162	51	108
31 Dec 20	-168	50	116
30 Sep 20	-172	51	121
30 Jun 20	-178	54	126
31 Mar 20	-179	56	128
31 Dec 19	-163	57	112
30 Sep 19	-146	55	98
30 Jun 19	-126	53	79
31 Mar 19	-107	48	63
31 Dec 18	-89	40	52
30 Sep 18	-80	38	42
30 Jun 18	-65	31	34
31 Mar 18	-54	26	27
31 Dec 17	-45	22	21

質の高い収益: RUBYは現在利益が出ていません。

利益率の向上: RUBYは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: RUBYの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。

成長の加速: RUBYの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: RUBYは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: RUBYは現在利益が出ていないため、自己資本利益率 ( -1187.4% ) はマイナスです。

Rubius Therapeutics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Recent updates

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Price target increased to US$7.63

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Price target increased to US$10.33

Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 2000 Growth Index

Rubius: Poor Data, Punishing Environment, Beaten Stock

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Price target decreased to US$7.60

Price target decreased to US$8.67

Price target decreased to US$9.40

Price target increased to US$23.00

Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics, Inc., Annual General Meeting, May 12, 2022

Rubius Looks Attractive Before AACR Data Readout

Price target increased to US$23.00

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Price target decreased to US$21.33

Price target decreased to US$23.33

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Price target decreased to US$25.67

Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Our Read On Rubius Therapeutics

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 3000E Value Index

Rubius Therapeutics, Inc. Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® in Ongoing Phase 1/2 Clinical Trial for Treatment of Advanced Solid Tumors

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Rubius Therapeutics EPS beats by $0.02

Insider exercised options and sold US$313k worth of stock

Rubius Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Announces Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240

New 90-day high: US$15.01

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Price target raised to US$13.25

Executive Chairman notifies of intention to sell stock

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: US$10.00

Price target raised to US$10.29

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Rubius Therapeutics, Inc. Provides an Operational Update

New 90-day high: US$8.83

New 90-day high: US$8.73

New 90-day high: US$5.92

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic Clinical Oncology Program, Rtx-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics EPS misses by $0.01

Rubius Therapeutics, Inc. Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

New 90-day low: US$4.62

Rubius Therapeutics, Inc. Appoints Jose Carmona as Principal Financial Officer, Principal Accounting Officer and Treasurer Effective as of October 1, 2020

New 90-day low: US$4.75

New 90-day low - US$4.81

New 90-day low - US$4.85

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - US$5.46

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去基準チェック /06